価格表

在庫・価格 : 2025年08月19日 01時45分 現在

商品名 商品コード メーカー 包装 価格 在庫 リスト
Anti-MHC Class I H2 Db, Mouse-Mono(28-14-8)
データシート
AM08080PU-N ACRアクリス アンチボディーズ
Acris Antibodies GmbH
0.5 mg ¥129,000
(未発注)
追加

在庫・価格 : 2025年08月19日 01時45分 現在

Anti-MHC Class I H2 Db, Mouse-Mono(28-14-8)

  • 商品コード:AM08080PU-N
  • メーカー:ACR
  • 包装:0.5mg
  • 価格: ¥129,000
  • 在庫:無(未発注)
使用文献
No. 文献情報 備考 参照
1 Lie WR et al. The specific binding of peptide ligand to Ld class I major histocompatibility complex molecules determines their antigenic structure. J. Exp. Med. 1991 Feb;173(2):449-59
Lie WR et al
1991/01/01
PubMed
2 Allen H et al. Beta 2-microglobulin is not required for cell surface expression of the murine class I histocompatibility antigen H-2Db or of a truncated H-2Db. Proc. Natl. Acad. Sci. U.S.A. 1986 Oct;83(19):7447-51
Allen H et al
1986/01/01
PubMed
3 Ozato K et al. Monoclonal antibodies to mouse MHC antigens. III. Hybridoma antibodies reacting to antigens of the H-2b haplotype reveal genetic control of isotype expression. J. Immunol. 1981 Jan;126(1):317-21
Ozato K et al
1981/01/01
PubMed
4 Woodward JG et al. Specific recognition of the product of a transferred major histocompatibility complex gene by cytotoxic T lymphocytes. Proc. Natl. Acad. Sci. U.S.A. 1982 Jun;79(11):3613-7
Woodward JG et al
1982/01/01
PubMed
5 Ozato K et al. Monoclonal antibodies to mouse MHC antigens. II. Antibodies to the H-2Ld antigen, the products of a third polymorphic locus of the mouse major histocompatibility complex. J. Immunol. 1980 Dec;125(6):2473-7
Ozato K et al
1980/01/01
PubMed
6 Levitsky HI et al. In vivo priming of two distinct antitumor effector populations: the role of MHC class I expression. J. Exp. Med. 1994 Apr;179(4):1215-24
Levitsky HI et al
1994/01/01
PubMed
7 Wang R et al. CD95-dependent bystander lysis caused by CD4+ T helper 1 effectors. J. Immunol. 1996 Oct;157(7):2961-8
Wang R et al
1996/01/01
PubMed
8 Lee SH et al. In vivo rejection of tumor cells dependent on CD8 cells that kill independently of perforin and FasL. Cancer Gene Ther. 2004 Mar;11(3):237-48
Lee SH et al
2004/01/01
PubMed
  • No.: 1
  • 文献情報:
    Lie WR et al. The specific binding of peptide ligand to Ld class I major histocompatibility complex molecules determines their antigenic structure. J. Exp. Med. 1991 Feb;173(2):449-59
    Lie WR et al
    1991/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 2
  • 文献情報:
    Allen H et al. Beta 2-microglobulin is not required for cell surface expression of the murine class I histocompatibility antigen H-2Db or of a truncated H-2Db. Proc. Natl. Acad. Sci. U.S.A. 1986 Oct;83(19):7447-51
    Allen H et al
    1986/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 3
  • 文献情報:
    Ozato K et al. Monoclonal antibodies to mouse MHC antigens. III. Hybridoma antibodies reacting to antigens of the H-2b haplotype reveal genetic control of isotype expression. J. Immunol. 1981 Jan;126(1):317-21
    Ozato K et al
    1981/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 4
  • 文献情報:
    Woodward JG et al. Specific recognition of the product of a transferred major histocompatibility complex gene by cytotoxic T lymphocytes. Proc. Natl. Acad. Sci. U.S.A. 1982 Jun;79(11):3613-7
    Woodward JG et al
    1982/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 5
  • 文献情報:
    Ozato K et al. Monoclonal antibodies to mouse MHC antigens. II. Antibodies to the H-2Ld antigen, the products of a third polymorphic locus of the mouse major histocompatibility complex. J. Immunol. 1980 Dec;125(6):2473-7
    Ozato K et al
    1980/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 6
  • 文献情報:
    Levitsky HI et al. In vivo priming of two distinct antitumor effector populations: the role of MHC class I expression. J. Exp. Med. 1994 Apr;179(4):1215-24
    Levitsky HI et al
    1994/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 7
  • 文献情報:
    Wang R et al. CD95-dependent bystander lysis caused by CD4+ T helper 1 effectors. J. Immunol. 1996 Oct;157(7):2961-8
    Wang R et al
    1996/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 8
  • 文献情報:
    Lee SH et al. In vivo rejection of tumor cells dependent on CD8 cells that kill independently of perforin and FasL. Cancer Gene Ther. 2004 Mar;11(3):237-48
    Lee SH et al
    2004/01/01
  • 備考:
  • 参照:
    PubMed